Home | Welcome to Contract Pharma   
Last Updated Thursday, December 18 2014

Print RSS Feed

Breaking News

Related Searches:
March 15, 2011
Incyte Corporation’s COMFORT-II, the second Phase III trial of investigational Janus kinase (JAK) inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis.  Read More »
March 15, 2011
Dr. Stuart Grant has been promoted to associate director of regulatory affairs and medical writing at ClinTec International.   Read More »
March 14, 2011
Elanco, Lilly’s animal health division, has made a one-time offer to acquire the animal health business of Janssen Pharmaceutica NV, a Johnson & Johnson company.   Read More »
March 14, 2011
PROLOR Biotech, Inc. is relocating its corporate office and R&D facility to a new, larger building located near its current site in the Weizmann Science Park in Nes Ziona, Israel.   Read More »
March 14, 2011
Lance Miyamoto has been appointed senior vice president of Human Resources, Catalent Pharma Solutions, Inc.   Read More »
March 14, 2011
Mark D’Souza has been appointed president and chief executive officer of Labopharm and a member of the board of directors.   Read More »
March 11, 2011
McNeil-PPC, Inc., a Johnson & Johnson subsidiary, has finalized the terms of a Consent Decree with the FDA.   Read More »
March 11, 2011
Dendreon Corp. received approval from the FDA for the expansion of its NJ manufacturing facility, allowing the company to significantly increase the availability of Provenge.  Read More »
March 11, 2011
Tolerx and GlaxoSmithKline’s Phase III DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint in patients with new-onset autoimmune type 1 diabetes.   Read More »
March 11, 2011
Sanofi-aventis and Regeneron Pharmaceuticals’ Phase III VITAL trial evaluating the investigational drug aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC) showed that adding aflibercept to the chemotherapy dr  Read More »
March 11, 2011
GNS Healthcare and Biogen Idec published results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies.   Read More »
March 10, 2011
Greg Plowman, M.D., Ph.D., has been appointed to lead Lilly’s oncology research efforts as the vice president of oncology research, and senior vice president of ImClone Systems research.  Read More »
March 10, 2011
Epizyme, Inc. has entered a worldwide partnership with Eisai Co. to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers.  Read More »
March 10, 2011
Commercial manufacturing revenues were up 16% to $148.7 million  Read More »
March 10, 2011
Catalent Pharma Solutions celebrates the 50th anniversary of its Schorndorf, Germany facility, which specializes in modified release technologies and clinical supply services.   Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On